STAT July 3, 2024
GSK and CureVac have restructured an ongoing partnership that gives the British pharma giant control over the development of experimental mRNA-based Covid and flu vaccines, the companies said Wednesday.
CureVac, the German biotech that focuses on mRNA vaccines, will receive an initial payment of €400 million upfront ($430 million) from GSK, and is eligible for another €1.05 billion ($1.1 billion) in future payments if certain milestones are hit. In exchange, GSK is taking full control over the development, manufacturing, and marketing of vaccines for seasonal flu and Covid that are currently in Phase 2 trials, and a bird flu vaccine in Phase 1 studies.
All of the vaccines were developed using CureVac’s mRNA technology. The two companies have been working...
Today's Sponsors
Today's Sponsor